As President of the CTF, Annette brings leadership experience in the academic world and pharma/biotech research enterprises in Europe and the U.S. Intrigued by the observation that the path from great basic discoveries to great clinical benefit is often inefficient, she joined the CTF to try to smooth this path for neurofibromatosis (NF), a rare genetic disorder. Her hope is that the CTF will benefit patients with NF and the larger rare disease community.
Previously, Annette served as head of the Oncology R&D department for a biotech company in Italy, was Oncology Group Leader at Janssen Pharmaceutica, and completed postdoctoral fellowships at Yale University and La Salpetriere, Paris. Her research has been internationally recognized and she has extensive experience liaising and negotiating with biotechnology and pharmaceutical companies.
Alliance for Rare Cancers I Jedi Rare Cancer Foundation
P.O. Box 683501, Park City, Utah 84068
The Alliance for Rare Cancers is a fiscally sponsored program of the Jedi Rare Cancer Foundation, a 501(c)(3) nonprofit organization, accepting tax-deductible donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-2610819. All donations are tax deductible as allowed by law.I
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.